We are live on ! Find out more
ADXN

Addex Therapeutics
ADXN

4 hedge funds and large institutions have $2.86K invested in Addex Therapeutics in 2026 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.01% less ownership

Funds ownership: 0.03% → 0.02% (-0.01%)

20% less funds holding

Funds holding: 5 → 4 (-1)

39% less capital invested

Capital invested by funds: $4.71K → $2.86K (-$1.85K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
4
Holders Change
-1
Holders Change %
-20%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$7

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$1.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
1
Morgan Stanley
New York
$1.89K +$7 +1 +0.3%
GI
2
GAMMA Investing
California
$509 – – –
RhumbLine Advisers
3
RhumbLine Advisers
Massachusetts
$450 – – –
SS
4
SBI Securities
Japan
$6 – – –
UBS Group
5
UBS Group
Switzerland
– -$1.2K -156 Closed

ADXN Hedge Fund Activity: Q1 2026 in Review

4 of the 8,142 institutional investors tracked by Wall St. Rank reported a position in Addex Therapeutics (ADXN) for Q1 2026, worth a combined $2.86K — down 39% from $4.71K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of ADXN and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.

The largest buyer was Morgan Stanley, adding an estimated $7. The largest seller was UBS Group, exiting entirely with an estimated $1.2K sold.

  • 4 institutional investors held Addex Therapeutics (ADXN) as of Q1 2026, down from 5 in Q4 2025.
  • Funds reported $2.86K of Addex Therapeutics stock for Q1 2026, down 39% quarter-over-quarter.
  • 0 funds opened new Addex Therapeutics positions in Q1 2026 and 1 closed out, a net change of -1 holder.
  • The largest Addex Therapeutics buyer in Q1 2026 was Morgan Stanley, an estimated $7 added.
  • The largest Addex Therapeutics seller in Q1 2026 was UBS Group, an estimated $1.2K sold.

Based on aggregated 13F filings for Q1 2026.